NANOBIOMOFS

Nanoscale Metal–Organic Frameworks for Biomedical Applications

 Coordinatore FUNDACIO INSTITUT CATALA DE NANOCIENCIA I NANOTECNOLOGIA 

 Organization address address: CAMPUS DE LA UAB EDIFICI Q ICN2
city: BELLATERRA (BARCELONA)
postcode: 8193

contact info
Titolo: Ms.
Nome: Marta
Cognome: Balza
Email: send email
Telefono: 34935868310

 Nazionalità Coordinatore Spain [ES]
 Totale costo 168˙896 €
 EC contributo 168˙896 €
 Programma FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call FP7-PEOPLE-2011-IEF
 Funding Scheme MC-IEF
 Anno di inizio 2012
 Periodo (anno-mese-giorno) 2012-03-01   -   2014-02-28

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    FUNDACIO INSTITUT CATALA DE NANOCIENCIA I NANOTECNOLOGIA

 Organization address address: CAMPUS DE LA UAB EDIFICI Q ICN2
city: BELLATERRA (BARCELONA)
postcode: 8193

contact info
Titolo: Ms.
Nome: Marta
Cognome: Balza
Email: send email
Telefono: 34935868310

ES (BELLATERRA (BARCELONA)) coordinator 168˙896.40

Mappa

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

drugs    bulk    surface    frameworks    synthesising    internal    gas    ligands    organic    applicant    metal    space    nanoscale    nanotechnology    biomedicine    drug    mofs    area   

 Obiettivo del progetto (Objective)

'The project NanoBioMOFs (Nanoscale Metal–Organic Frameworks for Biomedical Applications) is a step forward to the researcher’s work undertaken during his postgraduate studies which comprised synthesising bulk Metal–Organic Frameworks (MOFs) for applications in gas storage, gas and liquid separation and molecular sensing. MOFs can be obtained from the connection of metal centres and organic ligands through the space in such a way that the structures obtained can be extended in one–, two– or three–dimensions. The applicant wishes to extend his knowledge in the same research area but from a completely different viewpoint, synthesising MOFs at the nanoscale regime for applications in drug delivery. To date, nanoparticle systems (polymer, iron or gold nanoparticles) have been used as drug delivery agents. This methodology has attracted much attention as it can improve many of the drawbacks of conventional therapy including high doses, rapid clearance, poor pharmacokinetics and strong side effects. Porous MOFs can be also used as drug delivery carriers due to their tunable host–guest properties and the ability to post–modify their internal surface. Although MOFs are excellent candidates to deliver drugs, they cannot be used in the form of traditional bulk but they have to be miniaturized at the nanometre scale. The aim of this project will be the synthesis of known and novel biocompatible, water–resistant MOFs based on biological ligands at the nanoscale, loading of MOFs with anticancer drugs and check their in vitro safety and therapeutic efficacy for chronic diseases such as cancer. This project allows the applicant to conduct truly interdisciplinary and inter–sectoral research, complementing his expertise in synthetic and materials chemistry in nanotechnology (Catalan Institute of Nanotechnology) and biomedicine (Biotechnology and Biomedicine Institute) at laboratories with long–standing collaboration, unique validation models and and state–of–the–art infrastructure.'

Introduzione (Teaser)

One of the most promising material types of the 21st century has unprecedented surface area with largely empty internal space. Utilising biologically relevant molecules to synthesise them, scientists have developed sensors and drug-delivery vehicles.

Altri progetti dello stesso programma (FP7-PEOPLE)

SINANOTUNE (2011)

Dopant-surface interactions in silicon nanoclusters

Read More  

ESCODNA (2013)

European School of DNA Nanotechnology

Read More  

ROLE OF TCR AFFINITY (2008)

Study and modification of T-cell receptor structure to enhance anti-tumor activity

Read More